GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Gross Margin %

Eris Lifesciences (BOM:540596) Gross Margin % : 78.40% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Eris Lifesciences's Gross Profit for the three months ended in Mar. 2024 was ₹4,291 Mil. Eris Lifesciences's Revenue for the three months ended in Mar. 2024 was ₹5,473 Mil. Therefore, Eris Lifesciences's Gross Margin % for the quarter that ended in Mar. 2024 was 78.40%.


The historical rank and industry rank for Eris Lifesciences's Gross Margin % or its related term are showing as below:

BOM:540596' s Gross Margin % Range Over the Past 10 Years
Min: 78.8   Med: 82.74   Max: 85.71
Current: 80.92


During the past 12 years, the highest Gross Margin % of Eris Lifesciences was 85.71%. The lowest was 78.80%. And the median was 82.74%.

BOM:540596's Gross Margin % is ranked better than
93.01% of 987 companies
in the Drug Manufacturers industry
Industry Median: 46.53 vs BOM:540596: 80.92

Eris Lifesciences had a gross margin of 78.40% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Eris Lifesciences was -1.00% per year.


Eris Lifesciences Gross Margin % Historical Data

The historical data trend for Eris Lifesciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Gross Margin % Chart

Eris Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.11 79.72 80.33 78.80 80.91

Eris Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.65 82.96 81.10 81.62 78.40

Competitive Comparison of Eris Lifesciences's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eris Lifesciences's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Eris Lifesciences's Gross Margin % falls into.



Eris Lifesciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Eris Lifesciences's Gross Margin for the fiscal year that ended in Mar. 2024 is calculated as

Gross Margin % (A: Mar. 2024 )=Gross Profit (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=16112.5 / 19912.95
=(Revenue - Cost of Goods Sold) / Revenue
=(19912.95 - 3800.44) / 19912.95
=80.91 %

Eris Lifesciences's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=4290.8 / 5472.65
=(Revenue - Cost of Goods Sold) / Revenue
=(5472.65 - 1181.83) / 5472.65
=78.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Eris Lifesciences  (BOM:540596) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Eris Lifesciences had a gross margin of 78.40% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Eris Lifesciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eris Lifesciences (BOM:540596) Business Description

Traded in Other Exchanges
Address
Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines